%20(1).webp)
There are statistics that communicate scale, and then there are statistics that communicate collapse.
The figure that has emerged from the most recent NHS England data falls firmly into the second category. More than 668,000 people are currently waiting for an ADHD assessment in England. At one NHS trust, a backlog of 6,000 patients was assessed at a rate of three people per year between 2023 and 2024. At that pace, clearing the list would take 2,000 years.
This is not a metaphor. It is an arithmetic extrapolation from reported NHS data. And while that specific trust may represent an extreme, it reflects a system-wide failure that is now measurable, documented, and impossible to continue minimising.
ADHD is estimated to affect 2.5 million people in England. Hundreds of thousands of them are waiting for assessment. Many of them have been waiting for years. And as Henry Shelford, founder of ADHD UK, has said plainly: this healthcare failure costs lives and livelihoods.
The most recent NHS England data puts the number of people waiting for an ADHD assessment in England at 668,370. This is the largest figure on record, and it is not a static number. Demand continues to grow, with referrals increasing year on year as awareness of the condition expands and more people recognise symptoms in themselves or their children.
To contextualise this figure: approximately 2.5 million people in England are estimated to have ADHD. The 668,370 on waiting lists represent a substantial proportion of those affected who are actively seeking assessment but have not yet received it. Many more affected people have not yet sought assessment at all, and will in due course add to demand.
This is a medical need that has been present in the population all along. What has changed is the system's recognition of it, and the healthcare infrastructure's inability to keep pace with that recognition. For more on why ADHD diagnosis numbers are rising without any corresponding increase in the condition's actual prevalence, see our article on why awareness, not prevalence, is behind the ADHD surge.
The surge in ADHD assessment demand is not the result of overdiagnosis, manufactured illness, or social contagion. Research examining this question across multiple countries has consistently found that the prevalence of ADHD in the population has not increased. What has increased is the proportion of people with ADHD who are seeking assessment and diagnosis.
Two factors have been particularly significant in recent years.
Social media platforms including TikTok and Instagram have played a meaningful role in spreading awareness of what ADHD looks and feels like in daily life. People who have spent years or decades attributing their difficulties to personal failings encounter descriptions of ADHD that resonate with their own experience and seek assessment for the first time. This is, in principle, a positive development in terms of stigma reduction and access. It has produced a wave of demand that services were not built to absorb.
The pandemic created a separate and compounding effect. Lockdowns disrupted the structured routines that had, for many people with ADHD, provided an external scaffolding for daily functioning. When that structure disappeared, ADHD-related difficulties became harder to compensate for and harder to ignore. For significant numbers of people, the pandemic made long-standing struggles suddenly impossible to dismiss.
The most arresting single data point in the current picture comes from one NHS trust that reported 6,000 people on its waiting list between 2023 and 2024, while only three patients actually received an assessment during that period.
At that rate of throughput, clearing the existing backlog would take 2,000 years. New referrals would continue to arrive throughout those 2,000 years.
This is an extreme case, but it is not an isolated one. It is a concentrated expression of conditions that exist to varying degrees across much of the country: demand vastly outstripping capacity, specialist workforces that are too small to scale quickly, and a historical underinvestment in ADHD services that cannot be rapidly corrected.
Henry Shelford, founder of ADHD UK, described the picture clearly: "We see people waiting for years, and in some cases over a decade, for ADHD assessments. This healthcare failure costs lives and livelihoods."
The waiting list figures are not administrative statistics. They represent clinical risk that accumulates over years for the individuals behind each number.
ADHD affects how the brain regulates attention, impulse control, emotional responses, time perception, and executive function. Without assessment and appropriate support, these difficulties continue unmanaged and unaddressed. The consequences are measurable and documented.
Adults with unmanaged ADHD face significantly elevated rates of job loss, academic underperformance, financial instability, anxiety, depression, substance misuse, relationship breakdown, and involvement with the criminal justice system compared to neurotypical peers. Children with unrecognised ADHD fall behind educationally, develop secondary mental health difficulties, and carry the psychological consequences of being chronically misunderstood rather than appropriately supported.
Research consistently shows that timely assessment and treatment improve outcomes across all of these domains. Every year of delay is a year during which these risks accumulate. For a person waiting ten years for assessment, that is a decade of preventable impairment.
The clinical case for urgency is not contested. What has been contested, by the funding and structural choices made over decades, is whether ADHD deserves the resources its clinical importance requires.
Under the NHS constitution, patients have a legal right to begin non-urgent consultant-led treatment within 18 weeks of referral. This standard exists to ensure that clinical need is met in a timeframe that does not allow harm to accumulate through delay.
ADHD assessment is a consultant-led process. The 18-week standard should therefore apply. In practice, advocates and legal experts have documented that it is not being applied to ADHD and other mental health services in the way it is applied to physical health pathways. Patients waiting years for ADHD assessment have not had their 18-week rights enforced. Many are unaware that those rights exist.
ADHD UK has identified this gap as a basis for legal challenge and is preparing to use it as such.
ADHD UK is preparing a legal challenge against local health boards that are failing to meet the 18-week standard for ADHD assessment. The charity is also supporting individuals currently on waiting lists to bring legal complaints against their providers directly.
This follows earlier successful legal action in which ADHD UK blocked NHS England's proposal to cap how much work could be outsourced to external ADHD assessment providers through the Right to Choose scheme. That cap would have significantly restricted one of the most effective mechanisms patients have had for accessing assessment within a reasonable timeframe.
The legal route is not the preferred way to build a functioning healthcare system. It is the route that becomes necessary when systemic failures are not addressed through policy and investment. The fact that patient advocacy groups are now pursuing legal action reflects how far the gap has grown between what patients are legally entitled to and what the system is currently providing.
For more context on the Right to Choose restrictions that ADHD UK successfully challenged, see our article on Right to Choose latest updates.
The waiting list crisis is not limited to adults. Children and young people are also waiting years for assessment, and in some areas, the situation for younger patients is even more acute than for adults.
In Coventry and Warwickshire, more than 7,500 children and teenagers are on waiting lists for ADHD assessment, with some waiting up to ten years. The local Integrated Care Board temporarily paused adult referrals in an attempt to direct limited resources towards children already on the list, a decision that led to legal action from ADHD UK and drew significant national attention.
Dr Imogen Staveley, Chief Medical Officer for the Coventry and Warwickshire ICB, acknowledged directly that the situation was unacceptable. The fact that an NHS Chief Medical Officer is publicly describing services in their area as "not good enough" reflects a level of systemic strain that has moved beyond deniability.
For the full account of the Coventry and Warwickshire legal challenge and its implications, see our article on the NHS board suspension of ADHD referrals.
Understanding why delays matter requires understanding what ADHD actually is and how it affects the brain.
ADHD involves measurable differences in the functioning of several key brain regions. The prefrontal cortex, which is responsible for attention, planning, and impulse control, does not regulate focus as efficiently in ADHD as in neurotypical brains. The limbic system, which manages emotional responses, is affected by dopamine deficiency in ways that can lead to emotional volatility and restlessness. The basal ganglia, which helps coordinate communication between brain regions, can contribute to inattention and impulsivity when its functioning is disrupted. And the reticular activating system, which acts as a major relay for attention signals, can contribute to hyperactivity and impulsive behaviour.
These are neurological differences, not character deficits or behavioural choices. They respond to medication that increases dopamine and noradrenaline availability in the relevant brain systems, and to psychological and practical interventions that help people develop strategies to manage the executive function challenges these neurological differences create. Without assessment, none of these evidence-based interventions can be accessed.
One of the clearest indicators of the scale of unmet need that is now being recognised and, where access allows, addressed, is the trajectory of ADHD medication prescribing in England.
Prescriptions for ADHD medications rose from 137,885 patients in 2018 to 2019 to 302,125 patients in 2023 to 2024. That is more than double in five years. This trajectory reflects both the growing number of people receiving diagnoses and the evidence that medication is effective for a significant proportion of those diagnosed.
It also reflects, in the most concrete statistical terms, how much unmet need existed in the years before this increase. The people who received diagnoses and began medication after 2018 had not developed a new condition. They had a longstanding condition that was finally being recognised and treated. The backlog of 668,000 currently waiting represents a continuation of that unmet need.
The NHS Right to Choose pathway has been one of the most important mechanisms for improving access to ADHD assessment in recent years. It allows patients to choose from a broader range of approved providers rather than being limited to their local NHS service, enabling many to access assessment in months rather than years.
ADHD UK's earlier successful legal action blocked an attempt to cap the number of patients each Right to Choose provider could take per area, a change that would have dramatically reduced the pathway's effectiveness. The threat to the Right to Choose scheme illustrates a recurring pattern: access mechanisms that work for patients come under pressure when they are seen as costly or as drawing demand away from under-resourced local services.
Any meaningful response to the ADHD backlog needs to protect and expand access mechanisms like Right to Choose rather than restricting them. Restricting access to reduce visible demand does not reduce clinical need. It simply makes that need less visible and less accountable.
The picture that emerges from the data, from the legal challenges, and from the accounts of people waiting is one that points clearly to what is needed.
Enforceable waiting time standards must apply to ADHD as they apply to physical health pathways. If the 18-week standard cannot currently be met, there must be a transparent plan for how it will be met and accountability for progress towards that target.
Long-term investment in specialist ADHD services is essential. Current services cannot meet demand. Building the infrastructure to meet it requires resource commitment over a sustained period rather than piecemeal responses to immediate pressure.
Broader workforce involvement is the most practically achievable near-term route to expanding capacity. Training more clinicians, including GPs, community mental health nurses, pharmacists, and allied health professionals, to conduct ADHD assessments and provide ongoing care can meaningfully expand assessment throughput without waiting for specialist teams to be built from scratch. Many primary care professionals currently lack confidence in recognising and managing ADHD, and this is a gap that structured training can directly address.
Protection and expansion of Right to Choose and similar access mechanisms that allow patients to seek assessment outside their immediately local service when local waiting lists are unmanageable.
Research-informed policy that recognises the surge in demand as unmet clinical need finally coming to light rather than as a trend or fad to be managed down.
The scale of the backlog, and the 2,000-year projection that one trust's data produces, represent a failure that has been building for decades. ADHD services were designed and resourced for a patient population that was understood to be smaller, younger, and simpler than it actually is. The research on ADHD has matured enormously in the past twenty years. The services have not kept pace.
The most immediate and actionable part of the solution is training. Every clinician who becomes competent in ADHD assessment increases the system's capacity by a real and measurable amount. The workforce of primary care and community mental health professionals is considerably larger than the specialist ADHD workforce. Equipping that broader workforce with the skills to safely and effectively contribute to assessment and management is the most practical near-term route to reducing the backlog.
For healthcare professionals who want to develop that expertise and contribute directly to addressing the unmet need in their communities, our ADHD assessor training course and ADHD prescribing and management course provide CPD-certified education built around NICE guidelines and internationally recognised frameworks.
If you are on an NHS waiting list, ask your GP specifically about the Right to Choose pathway and whether it is still available in your area. This pathway allows referral to approved providers with shorter waiting lists. Its availability has changed in some regions, but it remains accessible in many areas.
If you have been told there is no local service and no pathway, ask your GP about Individual Funding Requests, which in some cases can fund access to alternative providers. Contact your local patient advocacy service for guidance on options in your specific area.
If you are considering taking legal action regarding waiting times, contact ADHD UK, which is currently supporting individuals pursuing legal complaints against providers who are failing to meet their obligations.
If you are considering private assessment, choose a CQC-registered provider with qualified clinicians, a comprehensive assessment process aligned with NICE guidelines, and clear information about what follow-up care including medication management will look like. For guidance on shared care arrangements that govern how medication is managed after a private diagnosis, see our article on shared care agreements.
While you wait, building documentation of how ADHD symptoms affect your daily life will be useful both during assessment and in any conversations with your GP about access to support before your assessment takes place.
How many people are waiting for NHS ADHD assessment in England?
NHS England data puts the current figure at 668,370. This is the largest recorded total, and new referrals continue to add to it every month.
What does the 2,000-year waiting list mean?
At one NHS trust that had 6,000 people waiting while only three were assessed in a year, it would take 2,000 years to clear the existing backlog at that rate of throughput. This is an extreme case, but it reflects the systemic imbalance between demand and capacity across much of the country.
Does the NHS 18-week standard apply to ADHD assessment?
Under the NHS constitution, patients have a right to begin non-urgent consultant-led treatment within 18 weeks of referral. ADHD assessment is consultant-led. Advocates and legal experts argue this standard should apply. In practice, it has not been enforced for ADHD services in the way it has for physical health pathways. ADHD UK is preparing legal challenges based on this gap.
Why has demand for ADHD assessment increased so much?
Research shows that ADHD prevalence has not increased. What has increased is awareness, driven by social media, reduced stigma, and the pandemic's amplification of ADHD-related difficulties. More of the people who have always had ADHD are now seeking assessment.
What can I do if I cannot access NHS ADHD assessment?
Ask your GP about the Right to Choose pathway, Individual Funding Requests, and neighbouring providers. Consider private assessment if accessible. Contact ADHD UK for guidance on legal options regarding waiting times.
Are ADHD medication prescriptions actually increasing?
Yes. ADHD medication prescriptions in England more than doubled between 2018-19 and 2023-24, reflecting both the growing number of diagnoses and the effectiveness of medication for many patients. The increase reflects unmet need finally being recognised rather than a new condition emerging.
A backlog that would take 2,000 years to clear at one trust's current pace is not a waiting list. It is a systemic failure, expressed in numerical terms that are difficult to look away from.
The 668,370 people behind that number are not statistics. They are people whose daily lives, mental health, education, careers, and relationships are affected by a condition that was always there, that the research has shown for decades how to treat, and that the healthcare system has not been resourced to address at the scale the clinical need requires.
The legal challenges being prepared by ADHD UK represent one route to accountability. Policy reform, long-term investment, and the urgent expansion of clinician training represent the routes to actual change. All of them are necessary. None of them will produce results quickly enough for the people who are waiting now.
What those people deserve, at minimum, is clarity about what options exist for them, honest acknowledgement from the system that has failed them, and the protections of a constitution whose standards have not been applied to their condition in the way they have been applied to others.
